SAN FRANCISCO and SUZHOU, China

旧金山和中国苏州

,

，

June 27, 2025

2025年6月27日

/PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that .

/PRNewswire/ -- 信达生物制药（Innovent Biologics, Inc.，简称“Innovent”）（港交所代码：01801），一家致力于开发、生产和销售用于治疗癌症、自身免疫疾病、心血管和代谢疾病、眼科疾病及其他重大疾病的高质量药物的世界级生物制药公司，宣布。

China's

中国的

National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (

国家药品监督管理局（NMPA）批准了玛仕度肽，这是一种首创的双胰高血糖素（GCG）/胰高血糖素样肽-1（GLP-1）双重激动剂。

GLP-1

GLP-1

) receptor agonist, for chronic weight management in Chinese adults with overweight or obesity. Mazdutide is the world's first dual GCG/

）受体激动剂，用于中国超重或肥胖成人慢性体重管理。玛珠肽是全球首个双重GCG/

GLP-1

GLP-1

receptor agonist approved for weight loss, offering a unique mechanism that enhances weight-loss efficacy while reducing visceral fat and delivering comprehensive metabolic benefits, named by

受体激动剂被批准用于减肥，提供了一种独特的机制，可增强减肥效果，同时减少内脏脂肪并带来全面的代谢益处，命名为

Fierce Pharma

烈性制药

as one of the top ten most anticipated drugs globally in 2025.

作为2025年全球十大最受期待药物之一。

Continue Reading

继续阅读

Mazdutide

玛仕度肽

The increasing prevalence of overweight and obesity in

超重和肥胖的患病率不断增加

China

中国

poses an urgent public health challenge requiring immediate intervention. In

构成了一个需要立即干预的紧迫公共卫生挑战。

April 2025

2025年4月

, the National Health Commission officially included 'Healthy Weight Management Action' in the 'Healthy China 2030' initiative. Under the updated plan, the national health authorities aim to build supportive environments for effective weight management, raise public awareness and behavior skills, and promote healthy lifestyles to curb rising rates of overweight and obesity.

，国家卫生健康委正式将“健康体重管理行动”纳入“健康中国2030”计划。根据最新方案，国家卫生部门旨在为有效体重管理构建支持性环境，提升公众意识和行为技能，并推广健康生活方式，以遏制不断上升的超重和肥胖率。

Aligned with these national priorities and the 2025 weight management campaign, the approval of mazdutide represents a timely and important milestone. Aiming to be an innovative leader in the cardiovascular and metabolic (CVM) disease area, Innovent is committed to accelerating the delivery of this drug to benefit a broad population in .

与这些国家优先事项和2025年体重管理运动保持一致，玛仕度肽的获批代表了一个及时且重要的里程碑。作为心血管和代谢（CVM）疾病领域的创新领导者，信达生物致力于加速推进该药物的上市进程，以造福广大患者群体。

China

中国

.

。

Scientific and effective treatment options for weight loss are urgently needed in

科学有效的减肥治疗方案迫切需要

China

中国

Overweight and obesity are chronic metabolic diseases characterized by excessive fat accumulation in the body. The pathogenesis of overweight and obesity includes genetic, metabolic, environmental, and behavioral factors. Obesity can significantly increase the risk of various diseases, such as cardiovascular and cerebrovascular, endocrine, specific tumors, respiratory, reproductive, and skeletal diseases, and can seriously affect quality of life.

超重和肥胖是以体内脂肪过度蓄积为特征的慢性代谢性疾病。超重和肥胖的发病机制包括遗传、代谢、环境及行为因素等多方面。肥胖可显著增加多种疾病的风险，如心脑血管、内分泌、特定肿瘤、呼吸系统、生殖系统及骨骼疾病，并严重影响生活质量。

[1]

[1]

. In

。在

China

中国

, over 500 million adults live with overweight (BMI ≥ 24 kg/m

，超过5亿成年人超重（BMI ≥ 24 kg/m

2

2

and ˂ 28 kg/m

且˂28公斤/平方米

2

2

) or obesity (BMI ≥ 28 kg/m

）或肥胖（BMI ≥ 28 kg/m

2

2

). Nearly 90% of obese adults have comorbidities, including metabolic dysfunction-associated fatty liver disease, which affects around 50% of adults with overweight and over 80% of adults with obesity. The World Obesity Federation (WOF) estimates that obesity costs

). 近90%的肥胖成年人存在共病，包括与代谢功能障碍相关的脂肪肝疾病，约50%的超重成年人和超过80%的肥胖成年人受其影响。世界肥胖联合会（WOF）估计，肥胖带来的花费

China

中国

around

周围

US$283.3 billion

2833亿美元

in GDP loss in 2020

2020年GDP损失

[2]

[2]

. With such heavy societal burdens, obesity and related chronic diseases have become major public health concerns in

。如此沉重的社会负担，使肥胖症和相关慢性疾病已成为主要的公共卫生问题

China

中国

and around the world.

并且遍布世界各地。

In response to the escalating obesity problem, several national policies and clinical guidelines have underscored the need for structured outpatient weight management and earlier pharmacological intervention. The National Health Commission's 'Notice on Effective Outpatient Settings and Management of Weight Management' encourages the development of optimized outpatient care models.

针对日益严重的肥胖问题，多项国家政策和临床指南强调了需要有结构化的门诊体重管理和更早的药物干预。国家卫生健康委员会发布的《关于有效开展门诊体重管理的通知》鼓励发展优化的门诊护理模式。

Additionally, 'Guidelines for the Diagnosis and Treatment of Obesity (2024 Edition)' recommended pharmacotherapy when lifestyle interventions fail to meet weight loss goals. The 'Guidelines for Long-term Weight Management and Clinical Application of Drugs for Obese Patients (2024 Edition)' issued by the Chinese Society of Endocrinology further advocates for initiating drug treatment early in patients with obesity-related comorbidities..

此外，《肥胖症诊疗指南（2024版）》推荐在生活方式干预未能达到减重目标时进行药物治疗。中华医学会内分泌学分会发布的《肥胖症患者长期体重管理及药物临床应用指南（2024版）》进一步主张对伴有肥胖相关并发症的患者早期启动药物治疗。

Mazdutide is supported by robust clinical data published in multiple high-impact journals, including

玛仕度肽得到了多项发表在高影响力期刊上的强有力临床数据的支持，包括

Nature

自然

, the

，这个

Lancet

柳叶刀

sub-journals, and the

子期刊，以及

New England Journal of Medicine

新英格兰医学杂志

. As the first marketed dual GCG/

. 作为首个上市的双重GCG/

GLP-1

GLP-1

receptor agonist , mazdutide has been recommended by multiple clinical guidelines in

受体激动剂，玛仕度肽已被多个临床指南推荐

China

中国

[3],[4],[5],[6]

[3],[4],[5],[6]

and expert consensus on obesity management on account of its innovative mechanism and solid evidence base.

由于其创新的机制和坚实的证据基础，成为肥胖管理的专家共识。

Multiple metabolic benefits of mazdutide in supporting weight management

玛仕度肽在支持体重管理方面具有多种代谢益处

GCG receptors are mainly expressed in the liver, and GCG receptor agonism can inhibit hepatic fat synthesis and promote hepatic lipolysis. As a dual GCG/

GCG受体主要在肝脏表达，GCG受体激动可抑制肝脏脂肪合成并促进肝脏脂解。作为一种双重GCG/

GLP-1

GLP-1

receptor agonist weight loss drug, mazdutide can deliver significant weight loss efficacy and metabolic benefits such as waist circumstance and liver fat content reductions to adults with overweight or obesity.

受体激动剂类减肥药马扎鲁肽可显著减轻超重或肥胖成人的体重，并带来诸如腰围和肝脏脂肪含量减少等代谢益处。

The approval of mazdutide was mainly based on data from GLORY-1, a Phase 3 pivotal clinical study conducted in Chinese adults with overweight or obesity. The primary endpoint and all key secondary endpoints of the study were successfully achieved in 2024. Results showed that at weeks 32 and 48, the percentage of body weight reduction from baseline and the proportions of participants with a body weight reduction of ≥5%，≥10% and ≥15% in the mazdutide 4 mg group and mazdutide 6 mg group were superior to those of the placebo group..

玛仕度肽的批准主要基于 GLORY-1 的数据，这是一项针对中国超重或肥胖成人的 III 期关键临床研究。该研究在 2024 年成功达到了主要终点和所有关键次要终点。结果显示，在第 32 周和第 48 周，玛仕度肽 4 mg 组和玛仕度肽 6 mg 组的体重较基线减少百分比，以及体重减少 ≥5%、≥10% 和 ≥15% 的参与者比例均优于安慰剂组。

Based on the efficacy estimand, at week 48, the mean percentage changes in body weight relative to baseline in the mazdutide 4 mg, mazdutide 6 mg, and placebo groups were −12.0%, −14.8%, and −0.5%, respectively;

基于疗效估计值，第48周时，mazdutide 4 mg组、mazdutide 6 mg组和安慰剂组相对于基线的体重平均百分比变化分别为-12.0%、-14.8%和-0.5%；

The proportion of participants with a body weight reduction ≥ 5% relative to baseline were 73.5%, 82.8%, and 11.5%, respectively; the proportion of participants with a body weight reduction ≥ 15% relative to baseline were 37.0%, 50.6%, and 2.1%, respectively;

体重较基线减少≥5%的参与者比例分别为73.5%、82.8%和11.5%；体重较基线减少≥15%的参与者比例分别为37.0%、50.6%和2.1%；

The mean changes in waist circumference relative to baseline were −9.5 cm, −11.0 cm, and −1.5 cm, respectively.

腰围相对于基线的平均变化分别为 -9.5 厘米、-11.0 厘米和 -1.5 厘米。

In addition, mazdutide reduced liver fat content in adults with overweight or obesity. Among participants with baseline liver fat content ≥ 10%, the mean percent change from baseline in liver fat content to week 48 were −65.85%, −80.24%, and −5.27% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively..

此外，mazdutide减少了超重或肥胖成人的肝脏脂肪含量。在基线肝脏脂肪含量≥10%的参与者中，到第48周时，mazdutide 4 mg组、6 mg组和安慰剂组的肝脏脂肪含量较基线的平均百分比变化分别为-65.85%、-80.24%和-5.27%。

The results of GLORY-1 study have been presented at the American Diabetes Association (ADA) Annual Meeting and published in the

GLORY-1研究的结果已经在美国糖尿病协会（ADA）年会上公布，并发表在

New England Journal of Medicine

新英格兰医学杂志

, which have received widespread attention from industry experts and scholars.

受到了业界专家和学者的广泛关注。

Mazdutide addresses a critical unmet need in

玛仕度肽满足了至关重要且未被满足的需求

China

中国

by offering effective treatment for weight reduction while also improving cardiometabolic indicators in adults with overweight or obesity. Its use may help reduce the long-term societal and economic burdens associated with obesity-related diseases.

通过为超重或肥胖的成年人提供有效的减重治疗，同时改善其心脏代谢指标。其使用可能有助于减轻与肥胖相关疾病带来的长期社会和经济负担。

Professor

教授

Linong Ji

李农基

, the Leading Principal Investigator of GLORY-1, Peking University People's Hospital,

北京大学人民医院GLORY-1项目首席研究员

stated, 'Obesity is a chronic disease that demands a coordinated societal response. With

声明说：“肥胖是一种慢性疾病，需要全社会的协调应对。随着

China

中国

facing a high prevalence of overweight and obesity, the associated cardiometabolic disease burdens continue to rise. There is an urgent need for weight-loss therapies that are both effective and safe, with proven cardiovascular and metabolic benefits. As the principal investigator of this novel dual GCG/.

面对高发的超重和肥胖问题，相关的心脏代谢疾病负担持续增加。迫切需要既有效又安全，并且具有经验证的心血管和代谢益处的减重疗法。作为这项新型双GCG研究的首席研究员/.

GLP-1

GLP-1

receptor agonist with a unique mechanism of action, I'm proud to see our clinical results recognized by

具有独特作用机制的受体激动剂，我很自豪看到我们的临床结果得到认可

China's

中国的

national regulatory authority and anticipate its subsequent approval for market launch. My fellow researchers and I hope mazdutide will become a valuable therapeutic option for Chinese adults with overweight or obesity.'

国家监管机构，并期待其随后批准上市。我和我的研究伙伴们希望，玛仕度肽能成为中国超重或肥胖成人的一个有价值的治疗选择。”

Dr. Lei Qian from Innovent Biologics,

来自信达生物的雷谦博士，

stated, 'Mazdutide represents the next-generation dual GCG/

声明称：“Mazdutide 代表了下一代双重 GCG/

GLP-1

GLP-1

receptor agonist. Its clinical development has been made possible by pooling the collective expertise of leading endocrinology experts across

受体激动剂。其临床开发得益于汇聚了内分泌学领域领先专家的集体专业知识，跨越了不同的机构和地域。

China

中国

, and its successful approval reflects the NMPA's high recognition of its clinical value and safety. This milestone marks another breakthrough for Innovent in the cardiovascular and metabolic fields. We hope mazdutide will provide another therapeutic option for Chinese adults with overweight or obesity, improve their quality of life, and alleviate societal burdens.

，其成功获批反映了国家药品监督管理局对其临床价值和安全性的高度认可。这一里程碑标志着信达生物在心血管和代谢领域取得了又一突破。我们希望玛仕度肽将为中国超重或肥胖的成年人提供另一种治疗选择，改善他们的生活质量，减轻社会负担。

Centered on patient needs and innovation, Innovent has established and will continue to expand its rich CVM pipeline with mazdutide as a cornerstone product, aiming to continuously address the public's growing demand for health and quality of life and to serve more patients.'.

以患者需求和创新为核心，信达生物已建立并将继续拓展其丰富的CVM产品管线，其中玛仕度肽作为核心产品，旨在不断满足公众对健康和生活质量日益增长的需求，服务更多患者。

About Obesity/Overweight

关于肥胖/超重

Obesity is a chronic metabolic disease with complex causes, and it serves as a major risk factor for a range of diseases including diabetes, fatty liver disease, cardiovascular and cerebrovascular diseases, kidney disease, joint disorders, sleep-disordered breathing, and cancer.

肥胖是一种由复杂原因引起的慢性代谢性疾病，同时也是糖尿病、脂肪肝、心脑血管疾病、肾脏疾病、关节紊乱、睡眠呼吸障碍和癌症等一系列疾病的重要的风险因素。

China

中国

has the world's largest population of individuals with overweight or obesity, a trend that is likely to rise

拥有世界上最多的超重或肥胖人口，这一趋势可能会继续上升。

[7]

[7]

. Obesity is associated with multiple comorbidities and is a major contributor to reduced life expectancy and quality of life. In 2019, overweight and obesity accounted for 11.1% of deaths from chronic non-communicable diseases in

. 肥胖与多种合并症相关，是导致寿命缩短和生活质量下降的主要因素。2019年，超重和肥胖占慢性非传染性疾病死亡人数的11.1%。

China

中国

, nearly doubling from 5.7% in 1990

，几乎比 1990 年的 5.7% 翻了一番

[8]

[8]

.

。

Despite the chronic nature of obesity and its need for long-term management, treatment options remain limited. While lifestyle interventions remain the cornerstone of treatment, many patients struggle to achieve or maintain meaningful weight reduction. This underscores the urgent need for safe, effective, and sustainable pharmacological interventions..

尽管肥胖症具有慢性特性，需要长期管理，但治疗选择仍然有限。虽然生活方式干预仍是治疗的基石，但许多患者难以实现或维持有效的减重效果。这凸显了对安全、有效且可持续的药物干预的迫切需求。

About Mazdutide

关于玛仕度肽

Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a dual GCG /

信达生物与礼来公司（Lilly）就双重GCG受体激动剂mazdutide的开发和潜在商业化达成独家许可协议，

GLP-1

GLP-1

receptor agonist, in

受体激动剂，在

China

中国

. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of

. 作为一种哺乳动物的氧肟酸肽（OXM）类似物，除了具有

GLP-1

GLP-1

receptor agonists on promoting insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, serum uric acid, liver enzymes, liver fat content and improved insulin sensitivity..

通过激活胰高血糖素受体，玛仕度肽除了在促进胰岛素分泌、降低血糖和减轻体重方面的作用外，还可能增加能量消耗并改善肝脏脂肪代谢。玛仕度肽在临床研究中展现了卓越的减重和降糖效果，同时减少腰围、血脂、血压、血尿酸、肝酶、肝脏脂肪含量，并改善胰岛素敏感性。

Mazdutide is approved by NMPA for chronic weight management in adults with overweight or obesity*; and mazdutide currently has another NDA accepted for review by NMPA, for glycemia control in adults with type 2 diabetes.

玛仕度肽获国家药监局批准用于成人超重或肥胖*症的慢性体重管理；此外，玛仕度肽还有另一项新药申请已获国家药监局受理，适应症为成人2型糖尿病的血糖控制。

Mazdutide has currently conducted seven Phase 3 clinical studies, including:

目前，玛仕度肽已开展七项III期临床研究，包括：

GLORY-1: A Phase 3 clinical study conducted in Chinese adults with overweight of obesity;

GLORY-1：一项在中国超重或肥胖成人中进行的III期临床研究；

GLORY-2: A Phase 3 clinical study conducted in Chinese adults with moderately to severely obesity;

GLORY-2：一项在中国中度至重度肥胖成人中进行的III期临床研究；

GLORY-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD);

GLORY-3：一项比较玛仕度肽与司美格鲁肽在中国伴有代谢相关脂肪性肝病（MAFLD）的超重或肥胖成人中的III期临床研究；

GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity;

GLORY-OSA：一项针对中国阻塞性睡眠呼吸暂停（OSA）和肥胖患者的III期试验；

DREAMS-1: A Phase 3 clinical study conducted in Chinese adults with untreated type 2 diabetes;

DREAMS-1：一项针对未治疗的中国成人2型糖尿病患者的III期临床研究；

DREAMS-2: A Phase 3 clinical study comparing mazdutide versus dulaglutide in Chinese adults with type 2 diabetes who have poor glycemia control with oral medication;

DREAMS-2：一项 Phase 3 临床研究，比较玛仕度肽与度拉糖肽在中国成人2型糖尿病患者中口服药物血糖控制不佳的情况下的疗效；

DREAMS-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity;

DREAMS-3：一项比较玛仕度肽与司美格鲁肽在中国成人2型糖尿病和肥胖患者中的III期临床研究；

Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and the other four studies are currently ongoing.

其中，GLORY-1、DREAMS-1 和 DREAMS-2 已经达到了主要终点，另外四项研究目前正在正在进行中。

In addition, several new clinical studies of mazdutide are initiated or planned, including:

此外，还启动或计划开展几项新的 Mazdutide 临床研究，包括：

A Phase 3 trial in adolescents with obesity;

一项针对青少年肥胖的三期临床试验；

New studies in patients with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF).

针对代谢功能障碍相关脂肪性肝炎（MASH）和射血分数保留的心力衰竭（HFpEF）患者的新研究。

*Mazdutide is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of:

*Mazdutide 适用于配合低热量饮食和增加体力活动，用于初始体重指数 (BMI) 为以下情况的成年患者进行慢性体重管理：

BMI ≥ 28 kg/m² (obesity); or

BMI ≥ 28 kg/m²（肥胖）；或

BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome and etc.).

BMI ≥ 24 kg/m²（超重）且至少存在一种与体重相关的合并症（如高血糖、高血压、血脂异常、脂肪肝或阻塞性睡眠呼吸暂停综合征等）。

About Innovent Biologics

关于信达生物

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases.

信达生物是一家领先的生物制药公司，成立于2011年，使命是为全球患者提供负担得起的高质量生物制药。公司发现、开发、生产和商业化针对一些最棘手疾病的创新药物。其开创性疗法治疗癌症、心血管和代谢、自身免疫和眼部疾病。

Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center..

信达生物已上市16款产品，有2个新药申请处于监管审查阶段，4项资产处于III期或关键临床试验，还有15种分子处于早期临床阶段。信达生物与超过30家全球医疗保健公司合作，包括礼来、赛诺菲、Incyte、LG化学和MD安德森癌症中心。

Guided by the motto, 'Start with Integrity, Succeed through Action' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit

信达秉持“诚信为本，行动致胜”的信条，坚持行业实践的最高标准，携手合作推进生物制药行业的发展，使一流药物能够广泛普及。欲了解更多信息，请访问

www.innoventbio.com

www.innoventbio.com

, or follow Innovent on Facebook and LinkedIn.

，或者在 Facebook 和 LinkedIn 上关注信达。

Statement:  Innovent does not recommend the use of any unapproved drug (s)/indication (s).

声明：信达不建议使用任何未经批准的药物/适应症。

Forward-looking statement

前瞻性声明

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', 'intend' and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements.

本新闻稿可能包含某些前瞻性陈述，这些陈述因其性质而受到重大风险和不确定性的影响。与信达相关的“预期”、“相信”、“估计”、“预计”、“意图”等词语及类似表达旨在识别某些此类前瞻性陈述。

Innovent does not intend to update these forward-looking statements regularly..

信达不打算定期更新这些前瞻性声明。

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict.

这些前瞻性陈述是基于信达生物管理层在作出该等陈述时对未来事件的现有信念、假设、期望、估计、预测和理解。这些陈述并非对未来发展的保证，且受风险、不确定性和其他因素的影响，其中部分因素超出信达生物的控制范围且难以预测。

Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions..

因此，由于我们业务、信达的竞争环境以及政治、经济、法律和社会状况的未来变化或发展，实际结果可能与前瞻性陈述中包含的信息有重大差异。

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

信达、信达的董事及员工假定：(a) 对于本网站所含的前瞻性陈述，不承担任何更正或更新的义务；且(b) 在任何前瞻性陈述未能实现或被证明不正确的情况下，不承担任何责任。

REFERENCES

参考文献

[1]

[1]

Multidisciplinary Clinical Consensus on Diagnosis and Treatment of Obesity (2021 edition), Chinese Journal of Endocrinology and Metabolism. 2021;37(11):959-972.

《肥胖症诊疗多学科临床共识（2021版）》，《中华内分泌代谢杂志》。2021;37(11):959-972。

[2]

[2]

Qin X, Pan J. The Medical Cost Attributable to Obesity and Overweight in China: Estimation  Based on Longitudinal Surveys. Health Econ. 2016;25(10):1291-1311. doi:10.1002/hec.3217

秦雪，潘杰。中国因肥胖和超重导致的医疗费用：基于纵向调查的估算。《健康经济学》。2016；25（10）：1291-1311。doi:10.1002/hec.3217

[3]

[3]

Guideline for Chronic Weight Management and Clinical Practice of Anti-obesity Medications (2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7): 545-564

《慢性体重管理及抗肥胖症药物临床实践指南（2024年版）》。《中华内分泌代谢杂志》，2024，40(7): 545-564。

[4]

[4]

Expert Consensus on Weight Management for Type 2 Diabetes Mellitus. International Journal of Endocrinology and Metabolism.2024,44(5):359-370

《2型糖尿病体重管理的专家共识》。《国际内分泌与代谢杂志》，2024年，第44卷，第5期，第359-370页。

[5]

[5]

Expert Consensus on Glucagon-like Peptide-1 Receptor Agonist Analogs Combined with Lifestyle Intervention for Weight Loss (2024 Edition). Chinese Journal of Diabetes, 2024

《胰高糖素样肽-1受体激动剂联合生活方式干预减重专家共识（2024年版）》. 《中华糖尿病杂志》, 2024年

[6]

[6]

Interpretation of National Health Commission of the People's Republic of China. National Clinical Practice Guideline on Obesity Management  (2024 Edition). Chinese Medical Journal, 2025, *105*(18): 1387-1391.

中华人民共和国国家卫生健康委员会解读，《中国肥胖管理临床实践指南》（2024年版），《中华医学杂志》，2025年，第105卷第18期：1387-1391页。

[7]

[7]

Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373-92

潘晓峰，王璐，潘安。中国肥胖症的流行病学及决定因素。《柳叶刀糖尿病与内分泌学》2021年；第9卷：373-92页。

[8]

[8]

Institute for Health Metrics and Evaluation. Global Health Data Exchange. GBD results tool. http://ghdx.healthdata.org/gbd-resultstool (accessed Jan 10, 2021).

健康指标与评估研究所。全球健康数据交换。GBD结果工具。http://ghdx.healthdata.org/gbd-resultstool（访问日期：2021年1月10日）。

SOURCE Innovent Biologics

来源：信达生物制药

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用